Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Withdrawn before enrolling · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and peripheral stem cell transplantation followed by trastuzumab in treating women who have metastatic breast cancer.
Key facts
- Study ID
- NCT00006123
- Run by
- Beth Israel Deaconess Medical Center
- People needed
- 0
- Starts
- 2000-07-01
- Expected to finish
- 2000-07-01
- Last updated by the study team
- 2018-05-16
Who can join
Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.